ConductScience.org, home

Paper34722189

Hepatocellular Carcinoma and the Role of Liver Transplantation: A Review.

Muhammad H and 9 others. J Clin Transl Hepatol, 2021. Cited by 24 papers, by iCite.

Cite this record

ConductScience Library. Hepatocellular Carcinoma and the Role of Liver Transplantation: A Review. Papers, record 34722189. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34722189

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Hepatocellular Carcinoma and the Role of Liver Transplantation: A Review.
PubMed
Journal
J Clin Transl Hepatol
PubMed
Year
2021
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
24
iCite
Relative citation ratio, by iCite
1.53
iCite
Revised in PubMed
2022-02-16
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Muhammad HHaris
2Tehreem AAniqa
3Ting PSPeng-Sheng
4Gurakar MMerve
5Li SYSean Young
6Simsek CCem
7Alqahtani SASaleh A
8Kim AKAmy K
9Kohli RRuhail
10Gurakar AAhmethttps://orcid.org/0000-0002-2221-9148

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
K08 CA237624NCI NIH HHSUnited StatesK08CA237624PubMed

Source NIH RePORTER

Download CSV of grants

References113

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
129551707Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study.J Hepatol2018https://conductscience.org/library/papers/29551707PubMed
231302190Immune checkpoint inhibitor therapy in solid organ transplant recipients: A patient-centered systematic review.J Am Acad Dermatol2020https://conductscience.org/library/papers/31302190PubMed
324002285Thirty-year outcomes of the national hepatitis B immunization program in Taiwan.JAMA2013https://conductscience.org/library/papers/24002285PubMed
426130250Liver transplantation for hepatocellular carcinoma: outcomes and treatment options for recurrence.Ann Gastroenterol2015https://conductscience.org/library/papers/26130250PubMed
518650514Sorafenib in advanced hepatocellular carcinoma.N Engl J Med2008https://conductscience.org/library/papers/18650514PubMed
630705718Serum biomarkers and risk of hepatocellular carcinoma recurrence after liver transplantation.World J Hepatol2019https://conductscience.org/library/papers/30705718PubMed
730878469AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review.Gastroenterology2019https://conductscience.org/library/papers/30878469PubMed
832908865Increased Surgical Complications but Improved Overall Survival with Adult Living Donor Compared to Deceased Donor Liver Transplantation: A Systematic Review and Meta-Analysis.Biomed Res Int2020https://conductscience.org/library/papers/32908865PubMed
917717454Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA.Ann Surg2007https://conductscience.org/library/papers/17717454PubMed
1022882750Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial.Am J Transplant2012https://conductscience.org/library/papers/22882750PubMed
1116527702The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence.Clin Gastroenterol Hepatol2006https://conductscience.org/library/papers/16527702PubMed
1230548884Alpha-Fetoprotein Decrease from > 1,000 to < 500 ng/mL in Patients with Hepatocellular Carcinoma Leads to Improved Posttransplant Outcomes.Hepatology2019https://conductscience.org/library/papers/30548884PubMed
1328682909Statins intake and risk of liver cancer: A dose-response meta analysis of prospective cohort studies.Medicine (Baltimore)2017https://conductscience.org/library/papers/28682909PubMed
1411391528Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival.Hepatology2001https://conductscience.org/library/papers/11391528PubMed
1519095497Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.Lancet Oncol2009https://conductscience.org/library/papers/19095497PubMed
1630967904Hepatocellular carcinoma recurrence after liver transplantation: Risk factors, screening and clinical presentation.World J Hepatol2019https://conductscience.org/library/papers/30967904PubMed
1729205416The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: An ERCHIVES study.Hepatology2018https://conductscience.org/library/papers/29205416PubMed
1823837134Important predictor of mortality in patients with end-stage liver disease.Clin Mol Hepatol2013https://conductscience.org/library/papers/23837134PubMed
192535924The role of liver transplantation in hepatobiliary malignancy. A retrospective analysis of 95 patients with particular regard to tumor stage and recurrence.Ann Surg1989https://conductscience.org/library/papers/2535924PubMed
2029107679
Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
Lancet Oncol2017https://conductscience.org/library/papers/29107679PubMed

See all 113 referencesDownload CSV of references

Cited by21

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 24 citations.

PMIDTitleJournalYearIn PapersSource
41357375Association of vascular invasion and tumor differentiation on post-liver transplant outcomes in patients with hepatocellular carcinoma.World J Transplant2025https://conductscience.org/library/papers/41357375PubMed
40962495From comics to care: exploring the education potential of graphic novel in organ transplantation journey.Med Humanit2026https://conductscience.org/library/papers/40962495PubMed
40191726COPB2 promotes hepatocellular carcinoma progression through regulation of YAP1 nuclear translocation.Oncol Res2025https://conductscience.org/library/papers/40191726PubMed
39797227Are Ki-67 and Procalcitonin Expression Levels Useful in Predicting the Biological Behavior of Hepatocellular Carcinoma After Liver Transplantation?J Clin Med2024https://conductscience.org/library/papers/39797227PubMed
39172301Hepatic Resection as the Primary Treatment Method for Hepatocellular Carcinoma After Orthotopic Liver Transplantation.Ann Surg Oncol2024https://conductscience.org/library/papers/39172301PubMed
38576752Liver transplantation for hepatocellular carcinoma in India: Are we ready for 2040?World J Transplant2024https://conductscience.org/library/papers/38576752PubMed
38098611Role of the immune system in liver transplantation and its implications for therapeutic interventions.MedComm (2020)2023https://conductscience.org/library/papers/38098611PubMed
37917059Racial Disparities in Candidates for Hepatocellular Carcinoma Liver Transplant After 6-Month Wait Policy Change.JAMA Netw Open2023https://conductscience.org/library/papers/37917059PubMed
37719959Fucoidan Ameliorates Ferroptosis in Ischemia-reperfusion-induced Liver Injury through Nrf2/HO-1/GPX4 Activation.J Clin Transl Hepatol2023https://conductscience.org/library/papers/37719959PubMed
37685524Risk of Recurrence of Hepatocarcinoma after Liver Transplantation: Performance of Recurrence Predictive Models in a Cohort of Transplant Patients.J Clin Med2023https://conductscience.org/library/papers/37685524PubMed
37296912Neoadjuvant and Adjuvant Systemic Therapies in Loco-Regional Treatments for Hepatocellular Carcinoma: Are We at the Dawn of a New Era?Cancers (Basel)2023https://conductscience.org/library/papers/37296912PubMed
36891706[Research progress and clinical application value of exosomal circRNAs in hepatocellular carcinoma].Zhonghua Gan Zang Bing Za Zhi2022https://conductscience.org/library/papers/36891706PubMed
36811666Efficient chemosensitizing and antimetastatic combinations of a naturally occurring trans-ferulic acid with different chemotherapies on an in vitro hepatocellular carcinoma model.Naunyn Schmiedebergs Arch Pharmacol2023https://conductscience.org/library/papers/36811666PubMed
36727232[MicroRNA 424-5p promotes the sensitivity of hepatocellular carcinoma cells to sorafenib by targeting Kinesin family member 23].Zhonghua Gan Zang Bing Za Zhi2022https://conductscience.org/library/papers/36727232PubMed
36437845Role of immunotherapy in downsizing hepatocellular carcinoma prior to liver transplantation.World J Transplant2022https://conductscience.org/library/papers/36437845PubMed
36291898Hepatocellular Carcinoma Recurrence and Mortality Rate Post Liver Transplantation: Meta-Analysis and Systematic Review of Real-World Evidence.Cancers (Basel)2022https://conductscience.org/library/papers/36291898PubMed
36268362Successful use of venous graft from native liver with hepatocellular carcinoma during living donor liver transplantation with no impact on recurrence rate: A retrospective cohort study.Ann Med Surg (Lond)2022https://conductscience.org/library/papers/36268362PubMed
36072797Progress in gallbladder cancer with lymph node metastasis.Front Oncol2022https://conductscience.org/library/papers/36072797PubMed
35936699The Combination of AFP and "Up-To-Seven" Criteria May Be a Better Strategy for Liver Transplantation in Chinese Cirrhotic HCC Patients.Front Oncol2022https://conductscience.org/library/papers/35936699PubMed
35444459HSPB11 is a Prognostic Biomarker Associated with Immune Infiltrates in Hepatocellular Carcinoma.Int J Gen Med2022https://conductscience.org/library/papers/35444459PubMed

See all 21 cited byDownload CSV of cited by

Genes11

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/34722189

GET https://conductscience.org/api/papers/v1/34722189/references?page=2